Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.

CONCLUSION: This indirect comparison of Phase III trials indicates that rIX-FP efficacy compares favorably versus other rFIX products for prophylaxis in hemophilia B.
PMID: 31094591 [PubMed - as supplied by publisher]

Source: Journal of Medical Economics - May 17, 2019 Category: Health Management Tags: J Med Econ Source Type: research